Clinical trials referenced in this document:
Documents that mention this clinical trial
Vaginal Ring Use in a Phase 3 Microbicide Trial: A Comparison of Objective Measures and Self-reports of Non-adherence in ASPIRE
Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial
Experiences with simultaneous use of contraception and the vaginal ring for HIV prevention in sub-Saharan Africa
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (UM1AI068633, UM1AI068615, UM1AI106707)
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute of Mental Health
Received: 18 September 2020
Accepted: 19 April 2021
First Online: 23 April 2021
: The study was approved by the following Institutional Review Boards/Ethics Committees and Drug Regulatory Authorities: Prevention Sciences Research Committee of the US National Institute of Allergy and Infectious Diseases; US Food and Drug Administration; National Health Sciences Research Committee of Malawi; University of North Carolina at Chapel Hill Institutional Review Board; Pharmacy, Medicines and Poisons Board of Malawi; University of Cape Town: Human Research Ethics Committee; South African Medical Research Council Ethics Committee; Human Research Ethics Committee: (Medical), University of Witwatersrand, Johannesburg; Medicines Control Council of South Africa; Joint Clinical Research Centre Institutional Review Board; Uganda National Council for Science and Technology; Johns Hopkins University School of Medicine Institutional Review Board; National Drug Authority of Uganda; Medical Research Council of Zimbabwe; Committee on Human Research, University of California—San Francisco; Joint Parirenyatwa Hospital and College of Health Sciences Research Ethics; Research Council of Zimbabwe; Medicines Control Authority of Zimbabwe. All participants provided written informed consent.
: Not applicable.
: The authors declare that they have no competing interests.